Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of denosumab on muscle strength and insulin sensitivity in postmenopausal women with type 2 diabetes
2024-510637-18-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of denosumab in postmenopausal osteoporosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Central Denmark Region. Primary endpoints: Muscle mass and strength change at 12 months and Insulin sensitivity change at 12 months. Planned start Mar 2024; status: authorised.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-510637-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510637-18-00.